鞘内自体骨髓干细胞治疗儿童自闭症:一项随机对照试验

IF 2.8 3区 医学 Q2 PSYCHIATRY
Narges Sharifzadeh MD, Ali Ghasemi MD, Jalil Tavakol Afshari MD, Fatemeh Moharari MD, Atefeh Soltanifar MD, Ali Talaei MD, Hamid Reza Pouryousof MD, Mahsa Nahidi MD, Mohammad Reza Fayyazi Bordbar MD, Maliheh Ziaee MD
{"title":"鞘内自体骨髓干细胞治疗儿童自闭症:一项随机对照试验","authors":"Narges Sharifzadeh MD,&nbsp;Ali Ghasemi MD,&nbsp;Jalil Tavakol Afshari MD,&nbsp;Fatemeh Moharari MD,&nbsp;Atefeh Soltanifar MD,&nbsp;Ali Talaei MD,&nbsp;Hamid Reza Pouryousof MD,&nbsp;Mahsa Nahidi MD,&nbsp;Mohammad Reza Fayyazi Bordbar MD,&nbsp;Maliheh Ziaee MD","doi":"10.1111/appy.12445","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this ethically approved randomized controlled trial, 32 ASD children aged 5-15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS-II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI-severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; <i>P</i> = .002).</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.</p>\n </section>\n </div>","PeriodicalId":8618,"journal":{"name":"Asia‐Pacific Psychiatry","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2020-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/appy.12445","citationCount":"10","resultStr":"{\"title\":\"Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial\",\"authors\":\"Narges Sharifzadeh MD,&nbsp;Ali Ghasemi MD,&nbsp;Jalil Tavakol Afshari MD,&nbsp;Fatemeh Moharari MD,&nbsp;Atefeh Soltanifar MD,&nbsp;Ali Talaei MD,&nbsp;Hamid Reza Pouryousof MD,&nbsp;Mahsa Nahidi MD,&nbsp;Mohammad Reza Fayyazi Bordbar MD,&nbsp;Maliheh Ziaee MD\",\"doi\":\"10.1111/appy.12445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>In this ethically approved randomized controlled trial, 32 ASD children aged 5-15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS-II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI-severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; <i>P</i> = .002).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Discussion</h3>\\n \\n <p>Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.</p>\\n </section>\\n </div>\",\"PeriodicalId\":8618,\"journal\":{\"name\":\"Asia‐Pacific Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2020-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/appy.12445\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia‐Pacific Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/appy.12445\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia‐Pacific Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/appy.12445","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 10

摘要

本研究旨在确定自体骨髓间充质干细胞(BMMSCs)治疗儿童自闭症谱系障碍(ASD)的安全性和有效性,并与常规治疗进行比较。方法将32例5 ~ 15岁的ASD儿童随机分为两组,一组接受自体骨髓间充质干细胞联合康复治疗和利培酮(干预组),另一组接受康复治疗和利培酮(对照组)。干预组在4周内鞘内注射2次自体骨髓间充质干细胞。采用儿童自闭症评定量表(CARS)、Gilliam自闭症评定量表-第二版(gar - ii)和临床总体印象(CGI)在基线以及干预后6个月和12个月对患者进行评估。结果干预组(n = 14)和对照组(n = 18)共32例患者完成研究,其中男性27例(84.4%)。平均年龄9.50±2.14岁。CARS总分、gar - ii自闭症指数和CGI总体改善在12个月内各组间无显著差异。然而,对于cgi -疾病严重程度,时间*组交互作用的主效应是显著的,干预组的改善更为显著(F = 6.719;P = .002)。鞘内注射自体骨髓间充质干细胞似乎是安全可行的,但治疗儿童ASD的临床疗效有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial

Introduction

This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).

Methods

In this ethically approved randomized controlled trial, 32 ASD children aged 5-15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.

Results

Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS-II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI-severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; P = .002).

Discussion

Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.80
自引率
0.00%
发文量
17
审稿时长
>12 weeks
期刊介绍: Asia-Pacific Psychiatry is an international psychiatric journal focused on the Asia and Pacific Rim region, and is the official journal of the Pacific Rim College of Psychiatrics. Asia-Pacific Psychiatry enables psychiatric and other mental health professionals in the region to share their research, education programs and clinical experience with a larger international readership. The journal offers a venue for high quality research for and from the region in the face of minimal international publication availability for authors concerned with the region. This includes findings highlighting the diversity in psychiatric behaviour, treatment and outcome related to social, ethnic, cultural and economic differences of the region. The journal publishes peer-reviewed articles and reviews, as well as clinically and educationally focused papers on regional best practices. Images, videos, a young psychiatrist''s corner, meeting reports, a journal club and contextual commentaries differentiate this journal from existing main stream psychiatry journals that are focused on other regions, or nationally focused within countries of Asia and the Pacific Rim.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信